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Abstract
Background: Mineralocorticoid receptor antagonists (MRAs) have been associated with improved patient outcomes
in patients with heart failure with reduced ejection fraction (HFrEF) but not preserved ejection fraction (HFpEF).
We conducted a systematic review and meta-analysis of selective and nonselective MRAs in HFrEF and HFpEF.
Methods: We searched Cochrane Central Register of Controlled Trials, MEDLINE and EMBASE. We included
randomized controlled trials (RCT) of MRAs in adults with HFpEF or HFrEF if they reported data on major adverse
cardiac events or drug safety.
Results: We identified 15 studies representing 16321 patients. MRAs were associated with a reduced risk of
cardiovascular death (RR 0.81 [0.75–0.87], I2 0%), all-cause mortality (RR 0.83 [0.77–0.88], I2 0%), and cardiac
hospitalizations (RR 0.80 [0.70–0.92], I2 58.4%). However, an a-priori specified subgroup analysis demonstrated
that these benefits were limited to HFrEF (cardiovascular death RR 0.79 [0.73–0.86], I2 0%; all-cause mortality
RR 0.81 [0.75–0.87], I2 0%; cardiac hospitalizations RR 0.76 [0.64–0.90], I2 68%), but not HFpEF (all-cause
mortality RR 0.92 [0.79–1.08], I2 0%; cardiac hospitalizations RR 0.91 [0.67–1.24], I2 17%). MRAs increased the
risk of hyperkalemia (RR 2.03 [1.78–2.31], I2 0%). Nonselective MRAs, but not selective MRAs increased the risk
of gynecomastia (RR 7.37 [4.42–12.30], I2 0% vs. RR 0.74 [0.43–1.27], I2 0%). Evidence was of moderate quality
for cardiovascular death, all-cause mortality and cardiovascular hospitalizations; and high-quality for hyperkalemia
and gynecomastia.
Conclusions: MRAs reduce the risk of adverse cardiac events in HFrEF but not HFpEF. MRA use in HFpEF increases the
risk of harm from hyperkalemia and gynecomastia. Selective MRAs are equally effective as nonselective MRAs, without
a risk of gynecomastia.
Keywords: Heart failure, Heart failure with reduced ejection fraction, Heart failure with preserved ejection fraction,
Mineralocorticoid receptor antagonists, Systematic review
Background
Heart failure (HF) has significant morbidity and is often
a result of impaired left ventricular myocardial function
[1]. HF with preserved ejection fraction (HFpEF) in-
volves impaired myocardial function with normal left
ventricle size and ejection fraction; in contrast, HF with
reduced ejection fraction (HFrEF) involves an enlarged
left ventricle size and reduced ejection fraction.
Evidence-based HF treatment reduces morbidity and
mortality in HFrEF [2]. HFpEF prevalence is rising due
to an ageing population, however, there are no treat-
ments which reduce morbidity and mortality [3]. Diag-
nosing HFpEF is often confounded by the occurrence of
similar symptoms in patients with multiple medical co-
morbidities [3]. The most prevalent risk factor for
HFpEF is hypertension [3]. Several RCTs have explored
the benefits of β-blockers [4], ARBs [5], ACEi [6], and
mineralocorticoid receptor antagonists (MRAs) [7] in
HFpEF and identified trends towards reduced cardiovas-
cular morbidity and mortality [8]. The lack of strong* Correspondence: mmrkobr@uwo.ca
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evidence in HFpEF treatment has led to considerable
treatment variation [9].
MRAs can be selective (e.g., eplerenone) or nonselec-
tive (e.g., spironolactone). Eplerenone was synthesized
through chemical modification of spironolactone in
order to enhance binding of mineralocorticoid receptors
while reducing off-target binding to progesterone or an-
drogen receptors [10]. Eplerenone is associated with
lower rates of impotence, gynecomastia or breast pain in
comparison to spironolactone [11, 12].
MRAs found initial use in HF exacerbations as di-
uretics in patients’ refractory to combined ACEi and
loop diuretic therapy [13]. However, spironolactone at
doses with no significant diuretic effect was found to
reduce cardiovascular mortality [14]. This effect was
presumably due to a reduction in myocardial and vas-
cular fibrosis [14]. This effect may arise from spirono-
lactone blocking aldosterone’s ability to stimulate
collagen synthesis at the myocardial level [15]. Spir-
onolactone and eplerenone have demonstrated signifi-
cant mortality benefit in HFrEF [11, 12]. In contrast,
MRAs in HFpEF do not reduce all-cause mortality,
however, they do reduce hospitalizations, improve
quality of life, and improve echocardiographic mea-
surements of diastolic function [16].
Chronically elevated aldosterone levels contribute to-
wards structural changes in the heart which promote
water retention, myocardial fibrosis, and increased
arrhythmogenicity [17]. MRAs in HFpEF improved
echocardiographic and biochemical measures of diastolic
function [16, 18]. However, a large prospective RCT in
HFpEF patients treated with spironolactone did not
demonstrate a significant benefit in terms of cardiovas-
cular outcomes [7].
Objectives
Our objectives were to evaluate the risks and benefits of
MRA usage in adults with HF. We were particularly
interested in differences between selective and nonselec-
tive MRAs in HFpEF and HFrEF in terms of cardiovas-
cular outcomes and adverse effects.
Methods
Our systematic review and meta-analysis complies with
the PRISMA statement [19].
Eligibility criteria
We included randomized controlled trials (RCTs) of
MRAs vs. placebo or standard therapy in adults
(≥18 years old) with HFpEF or HFrEF. Included trials
evaluated nonselective MRAs (e.g., canrenone, spirono-
lactone), and selective MRAs (e.g., eplerenone, finere-
none). Included trials contained at least one outcome of
interest: mortality (all-cause or cardiovascular), cardio-
vascular hospitalizations, hyperkalemia, or gynecomastia.
Literature search
We searched the Cochrane Central Register of
Controlled Trials (The Cochrane Library Issue 1, 2016),
MEDLINE (January 1995 to January 29, 2016), and
EMBASE (January 1995 to January 29, 2016) for articles
meeting our inclusion criteria. Our search strategy for
Ovid MEDLINE and EMBASE is in Appendix 1 and
our search strategy for the Cochrane Register of
Controlled Trials is in Appendix 2. Our search did
not have any language restrictions. We excluded re-
views, editorials, and conferences but not unpublished
studies or abstracts.
Study selection
We entered the retrieved citations into Reference
Manager (v12.0.3), and duplicate records were removed.
One investigator (NB) screened citations for relevance
based on their title and abstract. Both investigators
reviewed the full text articles of relevant articles for
study inclusion. Cohen’s kappa statistic was used to
quantify chance-corrected agreement between the inves-
tigators. Disagreements on study inclusion were resolved
through a consensus process of having a discussion be-
tween the two investigators.
Data collection and analysis
Both investigators extracted data independently from
included articles. We resolved disagreements during
data extraction by consensus. If data were incom-
plete or unclear we attempted to contact trial au-
thors. We extracted the following items from each
study: population (type of heart failure, study size),
intervention (MRA type), control (placebo, none,
other), and outcomes (all-cause mortality, cardiovas-
cular mortality, hospitalizations, hyperkalemia, and
gynecomastia/breast pain). We used each study’s def-
inition of these outcomes.
Risk of bias
Our risk of bias assessment was completed using the
Cochrane Risk of Bias Tool. It evaluates individual stud-
ies for several biases: selection, performance, detection,
attrition and reporting. We evaluated the quality of evi-
dence for each outcome using GRADE criteria [20],
which evaluates an outcome across studies based on risk
of bias, inconsistency, indirectness, imprecision and
publication bias.
Statistical analysis
We obtained the relative risk for each outcome from the
original study and used RevMan (version 5.3.5) and R
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[21, 22] to analyze data and generate figures. We used
the Mantel-Haenszel method with a 95% confidence
interval, and a random effects model to pool results. We
quantified statistical heterogeneity using the I2 statistic.
We interpreted an I2 value of 0–25% as low heterogen-
eity, 25–50% as moderate heterogeneity, and >50% as
high heterogeneity. A priori we established two hypoth-
eses to explain potential heterogeneity: HF type (HFpEF
and HFrEF), and MRA type (selective, or nonselective).




We screened 2566 citations, and selected 36 for full text
review. Of these, 15 articles [7, 11, 12, 18, 23–33] met
our inclusion criteria and were included in our system-
atic review (see Fig. 1). Overall, there was excellent
agreement on trial eligibility (Cohen’s kappa 94%). We
excluded articles from the systematic review because of
treatment in a non-HF setting (N = 4), lack of relevant
outcomes (N = 13), study duplication (N = 3), and not an
RCT design (N = 1).
Trial characteristics
Table 1 reports the trial characteristics of the 15 RCTs
containing 16321 patients. The patients had either
HFpEF (N = 4027) or HFrEF (N = 12294) and the MRA
treatment group was either nonselective, e.g., canrenone,
spironolactone, N = 11 RCTs, 6678 patients; or selective,
e.g., eplerenone, N = 4 RCTs, 9643 patients. Studies had
an average length of follow-up of 15 months.
Risk of bias within included trials
Table 2 reports the quality of included studies. Five
trials had unclear or absent allocation concealment
[23, 25, 26, 28, 30]. Two studies had inadequate
blinding and were of single-blind design [23, 32].
Two large studies were terminated early due to meet-
ing pre-defined benefit criteria [11, 33]. Another two
studies did not use intention-to-treat analysis. Overall,
loss-to-follow-up was low with a range of 0 to 6.6%.
Results of meta-analysis
Table 3 reports a summary of findings. We included out-
comes for cardiovascular death (7 RCTs), all-cause mor-
tality (12 RCTs), cardiac hospitalization (10 RCTs),
hyperkalemia (15 RCTs), and gynecomastia (N = 11
RCTs). Quality of evidence for cardiovascular death, all-
cause mortality, and cardiac hospitalization were rated
moderate; hyperkalemia and gynecomastia were rated
high using GRADE guidelines [20]. For each outcome,
HFrEF evidence was of high quality, but the quality of
evidence for HFpEF was of moderate quality for all-
cause mortality, cardiovascular death, and cardiac
hospitalizations.
Meta-analysis of cardiovascular death (see Fig. 2) re-
vealed a significant risk reduction, RR 0.81 [0.75–0.87],
I2 0% (low heterogeneity). Our analysis of cardiovascular
death by HF type indicated only a single trial of HFpEF
(TOPCAT) which had no significant reduction in car-
diovascular death [7]. Using either selective or nonselec-
tive MRA had a similar reduction in cardiovascular
death (Additional file 1: Figure S1).
Meta-analysis of all-cause mortality (see Fig. 3) re-
vealed a significant risk reduction, RR 0.83 [0.77–
0.88], I2 0% (low heterogeneity). HF type subgroups
indicated the benefit was limited to HFrEF. Use of
either a selective or nonselective MRA had a similar
reduction in all-cause mortality (Additional file 2:
Figure S2).
Meta-analysis of cardiac hospitalizations (see Fig. 4)
revealed a significant risk reduction, RR 0.80 [0.70–
0.92], I2 58.4% (high heterogeneity). Our a priori
subgroup analysis partially explained the heterogen-
eity within this outcome, as a significant reduction
in cardiac hospitalizations was found in the HFrEF
and nonselective MRA subgroups (Additional file 3:
Figure S3).
Hyperkalemia was significantly more common with
MRA use, RR 2.03 [1.78–2.31], I2 0% (low heterogen-
eity), see Fig. 5. Subgroup analysis by MRA or HF type
did not significantly influence the rate of hyperkalemia
(Additional file 4: Figure S4).
Gynecomastia was significantly more common with
MRA use, RR 3.28 [1.18–9.10], I2 81.7% (high heterogen-
eity), see Fig. 6. MRA type explained this heterogeneity
Fig. 1 Study selection flow diagram. Overview of process used
to identify studies for inclusion in the systematic review. Three
databases (MEDLINE, EMBASE, Cochrane) were searched for
relevant articles. After identification, studies were screened
against our inclusion criteria. Included studies were used in
our meta-analysis
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as selective MRAs did not produce significant
amounts of gynecomastia (RR 0.74 [0.43–1.27], I2 0%)
while nonselective MRAs did (RR 7.37 [4.42–12.30],
I2 0%).
Our analysis of funnel plots for each outcome ex-
cept gynecomastia revealed no significant asymmetry
(Additional file 5: Figure S5, Additional file 6: Figure S6,
Additional file 7: Figure S7, Additional file 8: Figure S8
and Additional file 9: Figure S9) and suggested the ab-
sence of publication bias. Two MRA subgroups within the
funnel plot for gynecomastia explained the asymmetry of
the plot (Additional file 9: Figure S9).
Discussion
Summary of evidence
15 trials evaluated the use of MRAs compared to
placebo or no treatment for HF. MRA use in patients
with heart failure was associated with a significant re-
duction in adverse cardiovascular outcomes: cardio-
vascular death (RR 0.81 [0.75–0.87], I2 0%), all-cause
Table 2 Risk of bias summary for each study included in the meta-analysis
Author Year Allocation concealment Blinding Intention to treat analysis Loss to follow-up (%) Early trial termination
Akbulut 2003 Unclear No Yes 0.0 No
Boccanelli 2009 Yes Yes Yes 6.2 No
Chan 2007 Unclear Yes Yes 0.0 No
Cicoira 2002 Unclear Yes Yes 6.6 No
Deswal 2011 Yes Yes No 4.3 No
Edelmann 2013 Yes Yes Yes 1.2 No
Edwards 2009 Unclear Yes No 2.7 No
Zannad 2011 Yes Yes Yes 1.2 Yes
Pitt 2003 Yes Yes Yes 0.3 No
Gao 2007 Yes Yes Yes 0.0 No
Pitt 2013 No (open label Aldactone) Yes Yes 0.0 No
Pitt 1999 Yes Yes Yes 0.0 Yes
Pitt 2014 Yes Yes Yes 3.8 No
Udelson 2010 Yes Yes Yes 0.0 No
Vizzardi 2014 Yes No Yes 0.0 No
Table 1 Overview of trials meeting systematic review inclusion criteria
Author Year Population Exp (N) Cont (N) Intervention Drug dose Follow-up (months)
Akbulut 2003 HFrEF, EF≤ 35%, NYHA III 35 35 spironolactone 25 mg daily 3
Boccanelli 2009 HFrEF, EF≤ 45%, NYHA II 215 223 canrenone 25 mg daily 12
Chan 2007 HFrEF, EF < 40%, NYHA I–III 23 25 spironolactone 25 mg daily 12
Cicoira 2002 HFrEF, EF≤ 45%, NYHA III 54 52 spironolactone 25 mg daily 12
Deswal 2011 HFpEF, EF≥ 50%, NYHA II–III 25 23 eplerenone 25 mg daily 6
Edelmann 2013 HFpEF, EF≥ 50%, NYHA II–III 213 209 spironolactone 25 mg daily 12
Edwards 2009 HFpEF, CKD stage 2–3 56 56 spironolactone 25 mg daily 9
Zannad 2011 HFrEF, EF≤ 35%, NYHA II 1364 1373 eplerenone 25–50 mg daily 21
Pitt 2003 MI + HFrEF, EF≤ 40% 3319 3313 eplerenone 25–50 mg daily 16
Gao 2007 HFrEF, EF < 45%, NYHA II–IV 58 58 spironolactone 20 mg daily 6
Pitt 2013 HFrEF, EF≤ 40%, CKD stage 2–3 63 65 spironolactone 25–50 mg daily 1
Pitt 1999 HFrEF, EF < 35%, NYHA III–IV 822 841 spironolactone 25–50 mg daily 24
Pitt 2014 HFpEF, EF≥ 45% 1722 1723 spironolactone 15–45 mg daily 40
Udelson 2010 HFrEF, EF≤ 35% NYHA II–III 117 109 eplerenone 50 mg daily 9
Vizzardi 2014 HFrEF, EF < 40%, NYHA I–II 65 65 spironolactone 25–100 mg daily 44
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mortality (RR 0.83 [0.77–0.88], I2 0%), and cardiac
hospitalizations (RR 0.80 [0.70–0.92], I2 58.4%). Our a
priori specified subgroup analysis demonstrated that
the benefits of MRAs are limited to HFrEF. Both se-
lective and nonselective MRAs increase the risk of
hyperkalemia (RR 2.03 [1.78–2.31], I2 0%), but
gynecomastia is limited to nonselective MRAs (nonse-
lective MRAs RR 7.37 [4.42–12.30], I2 0% vs. selective
MRAs RR 0.74 [0.43–1.27], I2 0%RR 7.37 [4.42–
12.30).
Fig. 2 Forest plot of cardiovascular death with MRA use in HF. Seven trials reported cardiovascular death rates when using MRAs in HF compared
to control. Our Forest plot has been subdivided according to HF type
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CI Confidence interval, RR Risk ratio
aHigh quality of evidence for HFrEF, single study for HFpEF
bSingle trial with confidence interval which crossed unity
cHigh quality of evidence for HFrEF, moderate quality evidence for HFpEF
dConfidence interval of data crossed unity
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Strengths and limitations
Our systematic review has strengths including adherence
to PRISMA reporting guidelines. In addition, our con-
clusions are based on evidence of moderate and high
quality (GRADE). HFpEF evidence was of moderate
quality, and HFrEF evidence was of high quality for car-
diovascular death and all-cause mortality. The quality of
evidence for cardiovascular death and all-cause mortality
was reduced due the evidence for MRA use in HFpEF
being limited to a single trial with large effect size [7],
and several smaller trials with confidence intervals
crossing unity [18, 27, 28]. For cardiovascular hospi-
talizations, the quality of evidence was reduced by
confidence intervals in HFpEF and HFrEF studies
crossing unity [7, 33]. Evidence for hyperkalemia and
gynecomastia with MRA usage was of high quality.
Overall, the evidence supporting MRA use in HFrEF
is based on a larger number of trials with significant
effect sizes for reducing adverse cardiac events. In
contrast, the evidence for MRA use in HFpEF is
based on a smaller number of trials, only one of
which had a significant reduction in cardiovascular
hospitalizations but no other adverse cardiac events
[7]. Finally, our conclusions supporting MRA usage in
HFrEF align with current American Heart Association
guidelines which recommend MRAs for patients with
HFrEF and NYHA class II-IV symptoms or following
acute MI complicated by HF and EF ≤ 40% [1].
Fig. 4 Forest plot of cardiovascular hospitalizations with MRA use in HF. Ten trials reported cardiovascular hospitalization rates with MRA use in
HF compared to control. Our Forest plot has been subdivided according to HF type
Fig. 3 Forest plot of all-cause mortality with MRA use in HF. Twelve trials reported all-cause mortality rates with MRA use in HF compared to
control. Our Forest plot has been subdivided according to HF type
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Implications
Current guidelines suggest MRAs are useful in treating
HFrEF and acute MI complicated by HF [1, 34]. We
demonstrate that treatment of HFpEF with MRAs does
not reduce adverse cardiac events. However, MRAs do
cause harm from hyperkalemia (NNH 26 [20–34]) and
gynecomastia (e.g., nonselective MRA, NNH 33 [19–63]).
Selective MRAs offer a slight advantage in terms of
no significant gynecomastia while having equivalent
reductions in adverse cardiac outcomes. We suggest
continued usage of MRAs in HFrEF, where there is a
significant reduction in adverse cardiac outcomes,
e.g., cardiovascular death (NNT 34 [26–50]), or all-
cause mortality (NNT 32 [24–45]). We suggest that
MRAs be avoided in HFpEF as they do not reduce
adverse cardiovascular outcomes.
Conclusions
Our systematic review provides evidence that MRAs
should not be used in HFpEF. MRA usage in HFpEF
provides a risk of hyperkalemia and/or gynecomastia
without reducing adverse cardiac events. In contrast,
MRA usage in HFrEF significantly reduces adverse car-
diac events.
Fig. 6 Forest plot of gynecomastia with MRA use in HF. Eleven trials reported gynecomastia rates with MRA use in HF compared to control. Our
Forest plot has been subdivided according to MRA type
Fig. 5 Forest plot of hyperkalemia with MRA use in HF. Fifteen trials reported hyperkalemia rates with MRA use in HF compared to control. Our
Forest plot has been subdivided according to HF type
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Appendix 1 Appendix 2
Additional files
Additional file 1: Figure S1. Forest plot of cardiovascular death in HF
with MRA use by MRA type. (EPS 2561 kb)
Additional file 2: Figure S2. Forest plot of all-cause mortality in HF
with MRA use by MRA type. (EPS 2763 kb)
Additional file 3: Figure S3. Forest plot of cardiovascular
hospitalization with MRA use by MRA type. (EPS 2740 kb)
Additional file 4: Figure S4. Forest plot of hyperkalemia with MRA use
by MRA type. (EPS 2919 kb)
Additional file 5: Figure S5. Funnel plot of cardiovascular death with
MRA use. (EPS 737 kb)
Additional file 6: Figure S6. Funnel plot of all-cause mortality with
MRA use. (EPS 736 kb)
Additional file 7: Figure S7. Funnel plot of cardiovascular
hospitalizations with MRA use. (EPS 710 kb)
Additional file 8: Figure S8. Funnel plot of hyperkalemia with MRA use.
(EPS 736 kb)
Additional file 9: Figure S9. Funnel plot of gynecomastia with MRA use.
(EPS 743 kb)
Abbreviations
HF: Heart failure; HFpEF: Heart failure with preserved ejection fraction;
HFrEF: Heart failure with reduced ejection fraction; MI: Myocardial infarction;
MRA: Mineralocorticoid receptor antagonist; NNH: Number needed to harm;
NNT: Number needed to treat; NYHA: New York Heart Association;
RCT: Randomized controlled trial; RR: Relative risk
Table 4 Ovid MEDLINE and EMBASE search strategy
1 Exp heart failure/ 376335/94836
2 Exp Cardiomyopathy/ 113241/78224
3 Exp Ventricular dysfunction/ 13819/28965
4 ((heart or cardiac or myocardial) adj2
(failure or decompensation)).ti,ab
211838/130125
5 ((congestive or chronic) adj2 heart
failure).ti,ab
67554/45613
6 ((ventric$) adj2 (failure or insufficien$ or
dysfunction$ or function$)).ti,ab
82523/54772
7 ((Reduced or preserved) adj2 "ejection
fraction").ti,ab.
6293/2856
8 (HFpEF or HFrEF).mp 2216/776




11 (animal$ not (human$ and animal$)).sh,hw. 3987846/4137327
12 10 NOT 11 501141/241626
13 exp Aldosterone Antagonist/ 32899/8124
14 (eplerenone or inspra or spironolactone or
aldactone or aldo$ or mineralocorticoid
receptor antagon$ or canren$ or fineren$).
ti,ab
134477/63667
15 (aldosterone adj2 antagon$). ti,ab 7857/2066
16 Or/13-15 134563/63667
17 16 NOT 11 111915/46794
18 12 and 17 20116/4880
19 (1995* or 1996* or 1997* or 1998* or 1999*
or 2000* or 2001* or 2002* or 2003* or
2004* or 2005* or 2006* or 2007* or 2008*
or 2009* or 2010* or 2011* or 2012* or
2013* or 2014* or 2015* or 2016*).dd
21741062/0
20 (1995* or 1996* or 1997* or 1998* or 1999*
or 2000* or 2001* or 2002* or 2003* or
2004* or 2005* or 2006* or 2007* or 2008*
or 2009* or 2010* or 2011* or 2012* or
2013* or 2014* or 2015* or 2016*).ed
0/16309819
21 19 or 20 21741062/16309819
22 18 AND 21 17787/3735
23 (book or conference paper or editorial or
letter or review).pt. not exp randomized
controlled trial/
4298634/3319843
24 (random sampl$ or random digit$ or
random effect$ or random survey or
random regression).ti,ab. not exp
randomized controlled trial/
69917/56001
25 (random$ or placebo$ or single blind$ or
double blind$ or triple blind$).ti,ab.
1177770/884750
26 25 not (23 or 24 or 11) 908857/648772
27 22 and 26 1802/503 = 2305
28 Remove duplicates from 27 1372/502 = 1874
(Search performed January 29, 2016)
Table 5 Cochrane database search strategy
1 exp heart failure 1412
2 exp Cardiomyopathy 133
3 exp Ventricular dysfunction 225
4 ((heart or cardiac or myocardial) near/2
(failure or decompensation)):ti,ab,kw
14941
5 ((congest* or chronic) near/2 "heart
failure"):ti,ab,kw
6158
6 (ventric* near (fail* or insufficien* or
dysfunction* or function*)):ti,ab,kw
9067
7 ((diastol* or systol*) near/2 (failure or
dysfunction* or function*)):ti, ab, kw
2866
8 ((Reduced or preserved) near/2
(ejection or fraction or “EF”)):ti, ab, kw
532
9 (“HFpEF” or “HFrEF”):ti, ab, kw 161
10 #1 or #2 or #3 or #4 or #5 or #6 or #7
or #8 or #9
21983
11 exp Aldosterone Antagonist* 44
12 (mineralocorticoid receptor antagonist*):ti,ab,kw 486
13 (eplerenone or inspra or spironolactone or
aldactone or canren* or fineren*):ti,ab,kw
1309
14 Aldosterone near/2 antagon* 393
15 #11 or #12 or #13 1661
16 #10 and #15 692
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